Protembis Secures €20M for Brain Protection Technology in TAVR

Protembis Secures €20M for Brain Protection Technology in TAVR

Protembis, a German Medtech company, has secured €20 million in venture debt financing from the European Investment Bank (EIB). This funding is aimed at advancing the development of the ProtEmbo® Cerebral Protection System, a next-generation device designed to protect the brain during transcatheter aortic valve replacement (TAVR) procedures. Unlike traditional methods, this device is engineered to significantly reduce the risks associated with TAVR, particularly brain injury from embolic material. The financial injection from a reputable institution underscores the technology’s potential to revolutionize patient care in cardiovascular procedures.

Funding and Support

EIB and InvestEU Collaboration

The €20 million raised comes as part of the InvestEU initiative, a program designed to encourage investment in innovative technologies across Europe. The European Investment Bank plays a crucial role in this initiative, with goals to promote research, development, and innovation. By 2027, InvestEU aims to generate an additional €372 billion in investments. This collaboration highlights the strategic alignment between institutional financial support and groundbreaking medical advancements. The InvestEU program’s overarching goal is to bolster the European Union’s capacity for innovation, particularly in critical sectors like medical technology.

The EIB’s involvement in Protembis’ project is noteworthy as it reflects the bank’s commitment to health tech advancements. The €20 million venture debt financing is part of a broader effort to enhance healthcare outcomes through technology. The EIB’s support goes beyond mere financing; it offers a vote of confidence in Protembis’ groundbreaking work. Such backing not only provides necessary funds but also amplifies the credibility and market readiness of the ProtEmbo® Cerebral Protection System. The bank’s participation aligns perfectly with European policy goals aimed at fostering technology that improves citizens’ health and well-being.

Protembis’ Previous Financial Milestones

Before securing this latest round of funding, Protembis successfully completed a €30 million Series B financing round in March 2024. This financial stability underscores the confidence stakeholders have in the company’s mission and technological advancements, further highlighted by the EIB’s continued support. The Series B financing primarily targeted the clinical validation and initial market roll-out of ProtEmbo®, laying a strong foundation for its further development and eventual market entry. Together, these funding milestones illustrate a strong financial roadmap for Protembis, giving the company room to breathe as it navigates the complexities of clinical trials and regulatory approvals.

The financial backing also highlights a broader trend of substantial investments within the Medtech industry. It underscores a heightened awareness and urgency in addressing cardiovascular complications, particularly those involving the brain during heart procedures. Endorsements from major financial institutions add layers of credibility, making it easier for Protembis to attract future investments and partnerships. This growing support network boosts the likelihood that the ProtEmbo® system will navigate the intricate pathways required for regulatory approval and widespread adoption, ultimately reaching hospitals and clinics around the world.

The ProtEmbo® Cerebral Protection System

Functionality and Design

The ProtEmbo® Cerebral Protection System is an intra-aortic filter device designed to line the roof of the aortic arch during TAVR procedures. This innovative device works by preventing dislodged embolic material from traveling to the brain, thus reducing the risk of strokes and cognitive decline. Its primary goal is to offer full brain protection during these critical heart interventions. The engineering behind the ProtEmbo® system reflects an emphasis on both efficacy and simplicity, aiming to address a critical need in cardiovascular treatment. The intra-aortic filter works by capturing potentially harmful debris, ensuring that it does not reach cerebral circulation.

The device’s design is also marked by its minimally invasive approach, a feature that sets it apart from other cerebral protection mechanisms. Rather than requiring complex surgical procedures, ProtEmbo® can be deployed using relatively simple techniques. This not only broadens the scope of its potential application but also minimizes additional risks to the patient. By focusing on a design that is both effective and easy to use, Protembis aims to make cerebral protection a standard component in TAVR procedures, thereby significantly improving patient outcomes.

Usability and Insertion Technique

One of the standout features of the ProtEmbo® device is its ease of use. It is inserted via an artery in the left wrist, making the procedure minimally invasive. This approach ensures that the insertion process is quick and less taxing for both healthcare providers and patients. Minimal invasiveness is a critical advantage, particularly for older patients or those with other health complications. The insertion technique, utilizing an artery in the left wrist, also allows for greater patient comfort and quicker recovery times, essential elements in improving overall patient experience and surgical outcomes.

The design prioritizes simplicity and reliability to ensure it can be seamlessly integrated into TAVR procedures. This user-friendly approach is crucial for widespread adoption, as it minimizes the learning curve for healthcare providers and reduces the likelihood of procedure-related complications. The ProtEmbo® device’s reliability ensures that it provides robust protection with minimal additional risk to the patient, achieving a balance between innovation and practicality. The ease of integration into existing TAVR procedures enhances its appeal to cardiac centers, paving the way for it to become a standard protective measure.

Clinical Trials and Market Access

Roadmap for Clinical Trials

The funds raised will significantly support ongoing and future clinical trials. These trials are essential to validate the effectiveness and safety of the ProtEmbo® system. Through rigorous testing, Protembis aims to demonstrate the clinical benefits of its device, paving the way for regulatory approvals and widespread adoption. Clinical validation is a critical step in ensuring that the ProtEmbo® system can meet stringent safety and efficacy standards set by regulatory bodies. Successful trials not only provide irrefutable data supporting the device’s effectiveness but also build trust among healthcare providers and patients.

The clinical trials will focus on a range of metrics, including the rate of embolic events, procedural success, and long-term outcomes. Enrollment in these trials will likely include a diverse patient demographic to ensure the results are generalizable. Achieving favorable outcomes in these trials will be pivotal in moving the ProtEmbo® system closer to market approval. Protembis is committed to transparency and scientific rigor throughout this process, aiming to publish the results in peer-reviewed journals and present them at major medical conferences, further establishing its credibility within the medical community.

Market Penetration Strategy

With around 430,000 patients expected to undergo TAVR procedures globally by 2025, the market potential for the ProtEmbo® system is substantial. Protembis’ strategy involves not only clinical validation but also effective market penetration, ensuring that their breakthrough technology reaches hospitals and cardiac centers worldwide. To achieve this, Protembis plans to engage in comprehensive training programs for clinicians, highlighting the ease of use and effectiveness of ProtEmbo®. Such initiatives will aim to smooth the transition from clinical trial success to real-world application, making the technology readily accessible.

A robust market penetration strategy will also involve partnerships with key stakeholders in the healthcare industry, including medical device distributors and hospitals. By fostering collaborations with these entities, Protembis can ensure a broad and rapid dissemination of its technology. Another component of the market strategy involves gaining endorsements from leading cardiologists and cardiovascular societies, whose support could significantly influence adoption rates. Protembis is poised to navigate complex regulatory landscapes and market dynamics to ensure ProtEmbo® achieves its full market potential, aiming to become a standard component in TAVR procedures.

Addressing the Problem in TAVR Procedures

Risks in TAVR and the Need for Protection

Transcatheter aortic valve replacement (TAVR) is a popular procedure for patients with severe aortic stenosis. However, a significant complication involves the risk of embolic debris dislodged during the procedure, which can lead to strokes or cognitive impairment. ProtEmbo® aims to eliminate this risk, offering a solution that can potentially save countless lives and enhance the quality of care. Because TAVR is often performed on elderly patients who are at higher risk for both cardiovascular and cerebral complications, the need for a reliable protection mechanism is urgent and paramount.

The ProtEmbo® system specifically addresses the most pressing risks associated with TAVR, making it a crucial addition to the procedural toolkit. Unlike other protection methods that might be overly invasive or partial in their coverage, ProtEmbo® is designed to offer comprehensive and reliable protection without adding significant procedural complexity. The risks of embolic events during TAVR are well-documented, and having an effective solution like ProtEmbo® can change the landscape of patient care, reducing one of the major concerns associated with the procedure.

Comparative Advantages

What sets ProtEmbo® apart from other solutions is its comprehensive brain protection mechanism. Traditional methods often leave gaps in coverage or are more invasive. The ProtEmbo® system not only ensures full protection but also emphasizes ease of use and minimal invasiveness, making it an appealing choice for both healthcare providers and patients. This comprehensive approach ensures that cerebral protection is integrated seamlessly into the TAVR process, reducing the need for additional steps or equipment that might complicate the procedure.

Another significant advantage is the device’s design, which is simpler and more user-friendly compared to alternative options. The focus on ease of use translates into reduced training time for medical staff, fewer procedural errors, and a smoother overall operation. By minimizing the added burden on healthcare providers, ProtEmbo® facilitates broader adoption and consistency in protection levels across different medical settings. The device’s reliability and simplicity make it a versatile tool, suitable for deployment in a variety of clinical environments, further expanding its potential impact on patient care.

Statements from Key Individuals

Insights from Protembis’ Leadership

Karl von Mangoldt and Conrad Rasmus, the Co-Chief Executive Officers of Protembis, expressed their gratitude for the EIB’s support. They stressed how this funding will enable the company to complete crucial clinical trials and progress towards market access, ultimately helping to protect patients from severe neurological complications during heart procedures. The leadership’s strong focus on the clinical and market aspects reflects Protembis’ commitment to turning innovative ideas into practical, patient-friendly solutions.

Their statements underscore the importance of the ProtEmbo® system in transforming cardiovascular care by mitigating serious risks associated with TAVR procedures. Von Mangoldt and Rasmus emphasized the synergy between institutional support and technological innovation, highlighting how the EIB’s backing is not just financial but also a strategic partnership essential for advancing ProtEmbo®’s development. Envisioning a future where the device becomes a standard in TAVR procedures, they see this funding as a vital step towards achieving that goal.

EIB’s Commitment to Health and Innovation

Nicola Beer, Vice-President of the EIB, highlighted the institution’s commitment to improving health and well-being across Europe. By supporting Protembis, the EIB underscores its dedication to fostering technological advancements that have transformative impacts on healthcare systems and patient outcomes. Beer’s statements reflect a broader vision of integrating innovative technologies to uplift public health, making ProtEmbo® a critical piece in the puzzle of advancing medical care.

The EIB’s involvement also signifies the bank’s broader role in facilitating cutting-edge research and its application in real-world scenarios. By investing in technologies like ProtEmbo®, the EIB aims to drive meaningful improvements in patient care, thereby contributing to the larger goal of enhancing healthcare across Europe. Nicola Beer’s comments indicate that this financial support is a part of a long-term strategy to integrate effective, innovative solutions into national health systems, highlighting the EIB’s mission to be a catalyst for positive change in the medical field.

Synthesis of Trends and Future Outlook

Increasing Investment in Health Tech

The continued support from financial institutions like the EIB signifies a growing trend of increased investments in health technology. These investments are not merely financial transactions but strategic moves aimed at uplifting healthcare quality through cutting-edge innovations. The focus on health tech highlights a collective recognition of the crucial role that advanced technologies can play in improving patient outcomes and optimizing healthcare delivery systems. This trend is likely to accelerate as new medical technologies, like ProtEmbo®, demonstrate their effectiveness in clinical settings.

The rise in investment also signals a shift in healthcare priorities, with a greater emphasis on preventative measures and innovative solutions. Financial backing from reputable institutions provides not only the necessary resources for development but also a level of credibility that can accelerate regulatory approvals and market adoption. The health tech sector’s growing financial support highlights a new era of enhanced patient care solutions driven by advanced technologies, reflecting a broader recognition of their transformative potential.

Collaborative Efforts in Health Innovations

Protembis, a renowned Medtech company based in Germany, has successfully secured €20 million in venture debt financing from the European Investment Bank (EIB). This significant funding is allocated to advance the development of the ProtEmbo® Cerebral Protection System, an innovative device designed to safeguard the brain during transcatheter aortic valve replacement (TAVR) procedures. TAVR is a minimally invasive surgery that replaces a failing aortic valve, but it often carries the risk of brain injury due to embolic material. The ProtEmbo® system is engineered to significantly mitigate these risks, setting it apart from traditional methods and enhancing patient safety.

This financial boost from a reputable institution like the EIB underscores the groundbreaking potential of Protembis’s technology. Not only does it highlight the confidence in Protembis’s capability, but it also marks a significant milestone in the journey toward transforming cardiovascular care, offering a safer and more effective solution for patients undergoing TAVR procedures.

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for subscribing.
We'll be sending you our best soon.
Something went wrong, please try again later